Market news

TScan Therapeutics (NASDAQ:TCRX) announced a strategic reorganization that includes a workforce reduction of approximately 75% as the company redirects resources toward an in vivo-engineered T cell receptor, or TCR-T, program targeting solid tumors. The Waltham, Massachusetts-based company plans to advance two product candidates into investigational new drug-enabling studies.

Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated data from Cohort C of the Phase 1 ALLOHA™ study; 100% (13/13) patients currently being tracked show complete donor chimerism Pauses further enrollment in Phase 3 ALLOHA-2™ study of TSC-101 due to insufficient capital; allowing data to mature and actively seeking collaboration partners Workforce reduction of approximately 75% and strategic

11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism...

Amgen (NasdaqGS:AMGN) has elected to terminate its research collaboration and license agreement with TScan Therapeutics focused on Crohn's disease target discovery. The decision ends Amgen's exclusive effort with TScan to identify and develop T-cell antigen targets for Crohn's disease. This change may affect Amgen's research pipeline in inflammatory bowel disease and influence its future approach to biotech partnerships. For broader context on the sector, consider exploring other...

Detailed price information for Alpha Cognition Inc (ACOG-Q) from The Globe and Mail including charting and trades.

First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process Cash and cash equivalents fund operations into the second quarter of 2027 WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapie

Actively enrolling patients across the US with anticipated topline data readout mid-2028WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the first patient has been infused with TSC-101 in the pivotal Phase 3 ALLOHA-2™ trial (NCT07702578). The patient, who was enrolle